Galderma: AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab's Significant Impact on Prurigo Nodularis

Extensive updates from broad and innovative portfolio also to be presented The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2

Related Keywords

United States ,American ,Clin Pharmacol ,Christian Marcoux ,Zach Randles Friedman ,Shawn Kwatra ,Rachel Mooney ,Adam Friedman ,Us Communications ,American Academy Of Dermatology ,Drug Administration ,George Washington University School Of Medicine ,Johns Hopkins University School Of Medicine ,Global Franchise Communications ,Annual Meeting ,George Washington University School ,Dermatology Atlas ,Associate Professor ,Johns Hopkins University School ,Therapeutic Dermatology ,Dermatological Skincare ,Full Spectrum ,Inclusive Atlas ,Breakthrough Therapy ,Injectable Aesthetics ,Rev Clin ,Communications Officer ,Franchise Communications ,Diese Gold Aktie ,Sichern Sie ,Galderma ,023 ,Gate ,Breaking ,Hase ,Results ,Emonstrate ,Nemolizumab ,Significant ,Impact ,Prurigo ,Nodularis ,